Wednesday, 28 September 2022

Bayers Eylea approved in Japan for child ratinopathy

Bayers Eylea approved in Japan for child ratinopathy
Bayers Eylea approved in Japan for child ratinopathy

Bayer announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Eylea (aflibercept) intravitreal injection 40 mg/mL for the treatment of preterm infants with retinopathy of prematurity (ROP).

Pradip Mahajan Wed, 09/28/2022 - 14:21

source https://www.pharmatutor.org/pharma-news/2022/bayers-eylea-approved-in-japan-for-child-ratinopathy

No comments:

Post a Comment

Pharma openings

  Opportunity for M.Pharm, Msc or PhD as Scientist at PGIMER M.Pharmacy or M.Sc 6 Year of Research Experience or PhD with 3 year of Experien...